208 related articles for article (PubMed ID: 35689083)
1. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study.
Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):113-118. PubMed ID: 35689083
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia A Canadian healthcare payer perspective.
Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
Can Urol Assoc J; 2023 Apr; 17(4):103-110. PubMed ID: 36486181
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore.
Chay J; Tung JYM; Su RJ; Aslim EJ; Wong C; Swan G; Chua WJ; Ho HSS; Finkelstein EA
J Med Econ; 2023; 26(1):1269-1277. PubMed ID: 37800562
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Fu S; Bhattacharyya SK; El-Arabi AM; Cutone BJ; McVary KT
PLoS One; 2022; 17(4):e0266824. PubMed ID: 35427376
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia.
Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Amorosi SL; Shore ND
J Health Econ Outcomes Res; 2021 May; 8(1):42-50. PubMed ID: 33987450
[No Abstract] [Full Text] [Related]
6. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
Erman A; Masucci L; Krahn MD; Elterman DS
BJU Int; 2018 Nov; 122(5):879-888. PubMed ID: 30113127
[TBL] [Abstract][Full Text] [Related]
7. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis.
Cornu JN; Zantek P; Burtt G; Martin C; Martin A; Springate C; Chughtai B
Eur Urol; 2023 Jun; 83(6):534-547. PubMed ID: 36964042
[TBL] [Abstract][Full Text] [Related]
8. Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis.
Franco JVA; Jung JH; Imamura M; Borofsky M; Omar MI; Escobar Liquitay CM; Young S; Golzarian J; Veroniki AA; Garegnani L; Dahm P
BJU Int; 2022 Aug; 130(2):142-156. PubMed ID: 34820997
[TBL] [Abstract][Full Text] [Related]
9. Medium-Term Real-World Outcomes of Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia: Water Vapor Thermal Therapy (Rezum)
Chin CP; Garden EB; Ravivarapu KT; Shukla D; Omidele O; Levy M; Qian D; Araya JS; Valenzuela R; Reddy A; Marshall S; Motola J; Nobert C; Gupta M; Small AC; Kaplan SA; Palese MA
J Endourol; 2022 Dec; 36(12):1559-1566. PubMed ID: 36039926
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan's public healthcare system.
Anezaki H; Endo F; Swan G; Takashima K; Rojanasarot S
J Med Econ; 2024; 27(1):554-565. PubMed ID: 38466193
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Private Payer and Patient Out-of-Pocket Costs Associated With the Surgical Management of Benign Prostatic Hyperplasia.
Wymer KM; Thao V; Narang G; Sharma V; Borah BJ; Cheney S; Humphreys MR
Urology; 2024 Feb; 184():87-93. PubMed ID: 38065310
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Cost-Effectiveness of Surgical Treatment Options for Benign Prostatic Hyperplasia.
Wymer KM; Narang G; Slade A; Sharma V; Thao V; Borah BJ; Rivera M; Cheney S; Humphreys MR
Urology; 2023 Jan; 171():96-102. PubMed ID: 36270339
[TBL] [Abstract][Full Text] [Related]
13. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Jung JH; Reddy B; McCutcheon KA; Borofsky M; Narayan V; Kim MH; Dahm P
Cochrane Database Syst Rev; 2019 May; 5(5):CD012832. PubMed ID: 31128077
[TBL] [Abstract][Full Text] [Related]
14. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of pharmacotherapy versus prostatic urethral lift as initial therapy for patients with moderate benign prostatic hyperplasia.
Tung JY; Aslim EJ; Ho HS; Chen C
Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):63-68. PubMed ID: 36342223
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.
Sønksen J; Barber NJ; Speakman MJ; Berges R; Wetterauer U; Greene D; Sievert KD; Chapple CR; Montorsi F; Patterson JM; Fahrenkrug L; Schoenthaler M; Gratzke C
Eur Urol; 2015 Oct; 68(4):643-52. PubMed ID: 25937539
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system.
De la Cuadra-Grande A; Rioja-Zuazu J; Domínguez-Esteban M; Torres E; Blissett R; Woodward E; Oyagüez I; Fernández-Arjona M
Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):499-510. PubMed ID: 36897833
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Minimally Invasive Procedures for Benign Prostatic Hyperplasia: A Cost-effectiveness Analysis.
Wu X; Zhou A; Heller M; Chi T; Kohlbrenner R
Radiology; 2023 Dec; 309(3):e230555. PubMed ID: 38085076
[TBL] [Abstract][Full Text] [Related]
19. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years.
Sievert KD; Schonthaler M; Berges R; Toomey P; Drager D; Herlemann A; Miller F; Wetterauer U; Volkmer B; Gratzke C; Amend B
World J Urol; 2019 Jul; 37(7):1353-1360. PubMed ID: 30283994
[TBL] [Abstract][Full Text] [Related]
20. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Plosker GL; Goa KL
Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
